Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05137665 · ClinicalTrials.gov registry record

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

A clinical trial of Amyotrophic Lateral Sclerosis and Movement Disorders, sponsored by Target ALS Foundation.

Recruiting
Registry status
1,000
Enrollment target
12
Study locations

NCT05137665 is a study of Amyotrophic Lateral Sclerosis and Movement Disorders that is actively recruiting participants, run by Target ALS Foundation. The registered enrollment target is 1,000 participants, above the 888-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (13% higher). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05137665, a study of Amyotrophic Lateral Sclerosis and Movement Disorders, is actively recruiting participants, sponsored by Target ALS Foundation.

RECRUITING
Registry status
1,000 participants
Enrollment target
12
Study locations

Study Summary

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Conditions Studied

Amyotrophic Lateral Sclerosis Movement Disorders Motor Neuron Disease Degenerative Disorder

Study Locations (12)

Other

  • Instituto Roosevelt - Bogotá
  • CHALS-CCT UPR MScience - San Juan

Arizona

  • Barrow Neurological Institute - Phoenix

California

  • University of California San Diego - San Diego

District of Columbia

  • Georgetown University - Georgetown

Florida

  • Mayo Clinic - Jacksonville

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2021-06-01
Est. Completion 2031-12-31

Sponsor

Target ALS Foundation

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05137665

The ClinicalTrials.gov registry entry for NCT05137665 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 888-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (13% higher). The listed sponsor is Target ALS Foundation, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT05137665 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05137665 about?

NCT05137665 is a clinical study titled "Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures". The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amy...

What is the current status of trial NCT05137665?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-06-01. Estimated completion is 2031-12-31.

What conditions does trial NCT05137665 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Motor Neuron Disease, Degenerative Disorder.

Who is sponsoring clinical trial NCT05137665?

This trial is sponsored by Target ALS Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05137665 being conducted?

This trial has 12 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Movement Disorders

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.